Wednesday, June 10, 2026
🇺🇸 FDA

pharma · No medical condition. · Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty Ltd

Anaxis Pharma clinical programs — 642 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Anaxis Pharma projects

642 ClinicalTrials.gov programs sponsored by Anaxis Pharma.

Anaxis Pharma has 642 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

642 programs

Clinical programs

Page 1 of 14

  1. -, Rozanolixizumab

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  2. -, Rozanolixizumab

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  3. 0600-PG-PSC-218

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis with or without controlled asthma

    phase 3 small molecule active

    1 trial

  4. 060018-PG-PSC-217

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis with or without asthma due to clinically relevant sensitisation to grass and olive pollen.

    phase 3 small molecule active

    1 trial

  5. 0796-19

    Lacuna Pharma Pty Ltd

    Menière's disease

    phase 3 small molecule active

    1 trial

  6. 131I-TLX-101-003

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 3 small molecule active

    1 trial

  7. 410701BS

    Lacuna Pharma Pty Ltd

    Plaque psoriasis

    phase 3 small molecule active

    1 trial

  8. 72189812

    Lacuna Pharma Pty Ltd

    Bipolar I Disorder

    phase 3 small molecule active

    1 trial

  9. 747-308

    Lacuna Pharma Pty Ltd

    Biliary Atresia, Post-hepatoportoenterostomy

    phase 3 small molecule active

    1 trial

  10. A011-14

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension (PAH)

    phase 3 small molecule active

    1 trial

  11. A35-004

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS)

    phase 3 small molecule active

    1 trial

  12. AC-055-315

    Lacuna Pharma Pty Ltd

    Pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  13. ACE-CL-006

    Lacuna Pharma Pty Ltd

    High Risk Chronic Lymphocytic Leukaemia

    phase 3 small molecule active

    1 trial

  14. ACE-CL-007

    Lacuna Pharma Pty Ltd

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  15. ACE-CL-311 (AMPLIFY)

    Lacuna Pharma Pty Ltd

    Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

    phase 3 small molecule active

    1 trial

  16. ACE-LY-308

    Lacuna Pharma Pty Ltd

    Mantle Cell Lymphoma

    phase 3 small molecule active

    1 trial

  17. ACP-101-302

    Lacuna Pharma Pty Ltd

    Hyperphagia related behaviour associated with Prader-Willi Syndrome (PWS)

    phase 3 small molecule active

    1 trial

  18. ACP-204-008

    Lacuna Pharma Pty Ltd

    Alzheimer's Disease Psychosis

    phase 3 other active

    1 trial

  19. ACP-204-013

    Lacuna Pharma Pty Ltd

    Lewy body Dementia psychosis (LBDP)

    phase 3 other active

    1 trial

  20. ADX-324-301

    Lacuna Pharma Pty Ltd

    Hereditary Angioedema

    phase 3 small molecule active

    1 trial

  21. AG348-C-020

    Lacuna Pharma Pty Ltd

    Anemia in subjects with sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  22. AG348-C-022

    Lacuna Pharma Pty Ltd

    Pyruvate Kinase Deficiency

    phase 3 small molecule active

    1 trial

  23. AG348-C-023

    Lacuna Pharma Pty Ltd

    Pyruvate Kinase Deficiency

    phase 3 small molecule active

    1 trial

  24. AMAG-FER-CKD-354

    Lacuna Pharma Pty Ltd

    Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chronic Kidney Disease (CKD)

    phase 3 small molecule active

    1 trial

  25. AMAG-FER-IDA-352

    Lacuna Pharma Pty Ltd

    Iron Deficiency Anemia (IDA)

    phase 3 small molecule active

    1 trial

  26. AMIR-FDC

    Lacuna Pharma Pty Ltd

    Arterial Hypertension

    phase 3 small molecule active

    1 trial

  27. APG2575AG301

    Lacuna Pharma Pty Ltd

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  28. APG2575CC301

    Lacuna Pharma Pty Ltd

    Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  29. APG2575CG301

    Lacuna Pharma Pty Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  30. APG2575MG301

    Lacuna Pharma Pty Ltd

    Newly Diagnosed Higher Risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  31. APL-2

    Lacuna Pharma Pty Ltd

    Geographic Atrophy Secondary to Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  32. APL2-C3G-310

    Lacuna Pharma Pty Ltd

    complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)

    phase 3 small molecule active

    1 trial

  33. ARN-509-003

    Lacuna Pharma Pty Ltd

    Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  34. ATN-106

    Lacuna Pharma Pty Ltd

    Congenital antithrombin deficiency

    phase 3 small molecule active

    1 trial

  35. ATN-108

    Lacuna Pharma Pty Ltd

    Acquired Antithrombin Deficiency (Heparin Resistance)

    phase 3 small molecule active

    1 trial

  36. AV-299-23-301

    Lacuna Pharma Pty Ltd

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  37. AV-951-20-304

    Lacuna Pharma Pty Ltd

    Renal cell carcinoma

    phase 3 small molecule active

    1 trial

  38. AV001

    Lacuna Pharma Pty Ltd

    Post-surgical neuropathic pain

    phase 3 small molecule active

    1 trial

  39. BCX7353-304

    Lacuna Pharma Pty Ltd

    Hereditary Angioedema (HAE)

    phase 3 small molecule active

    1 trial

  40. BHV2000-301

    Lacuna Pharma Pty Ltd

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  41. BHV4157-303

    Lacuna Pharma Pty Ltd

    Obsessive Compulsive Disorder

    phase 3 small molecule active

    1 trial

  42. C5041006

    Lacuna Pharma Pty Ltd

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  43. CPT for Allergic rhinoconjunctivitis to…

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Dermatophagoides farinae

    phase 3 small molecule active

    1 trial

  44. CRN00808-08

    Lacuna Pharma Pty Ltd

    Acromegaly

    phase 3 small molecule active

    1 trial

  45. CRN00808-09

    Lacuna Pharma Pty Ltd

    Acromegaly

    phase 3 small molecule active

    1 trial

  46. CRN00808-12

    Lacuna Pharma Pty Ltd

    Carcinoid syndrome

    phase 3 small molecule active

    1 trial

  47. CRN04894-12

    Lacuna Pharma Pty Ltd

    Classic Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    1 trial

  48. CRN04894-13

    Lacuna Pharma Pty Ltd

    Classic congenital adrenal hyperplasia

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Anaxis Pharma have?

642 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.